FDA Issues Final Guidance on Best Practices for Convening a GRAS Panel
The U.S. Food and Drug Administration (FDA) has issued a final guidance, titled, Best Practices for Convening a GRAS Panel. Although, in most cases, general recognition of safety can be supported without convening a GRAS panel, the guidance provides information to those assembling an expert GRAS panel.
GRAS panels evaluate whether a substance is safe under the conditions of its intended use in human or animal food, based on publicly available scientific data and information.